Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSL1 | P33121 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 15/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117504 | 0.86 | DGAT1 (0.50) | ACSL1DGAT1GCGRFAAHEPHX2 | |
| SCHEMBL10185420 | 0.86 | DGAT1 (0.66) | ACSL1DGAT1 | |
| SCHEMBL13117505 | 0.83 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL10186138 | 0.79 | EPHX2 (0.53) | DGAT1GCGRFAAHEPHX2 | |
| SCHEMBL664113 | 0.79 | DGAT1 (0.56) | DGAT1RAB9A | |
| SCHEMBL10184323 | 0.79 | DGAT1 (0.56) | DGAT1RAB9A | |
| SCHEMBL664114 | 0.79 | DGAT1 (0.56) | DGAT1RAB9A | |
| SCHEMBL10184403 | 0.78 | DGAT1 (0.54) | DGAT1FAAHEPHX2 | |
| SCHEMBL10186156 | 0.76 | NPC1 (0.52) | DGAT1GCGRFAAHEPHX2RAB9A | |
| SCHEMBL10185053 | 0.76 | MLYCD (0.49) | DGAT1FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | ACSL1 508/4885DGAT1 1/4885GCGR 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.